Efficacité et tolérance du nintédanib chez des patients atteints de pneumopathie interstitielle diffuse associée à la sclérodermie systémique (SSc-PID) en fonction de l’indice de masse corporelle (IMC) à l’inclusion : analyse en sous-groupes de l’étude SENSCIS
S. Jouneau(Inserm), CP Denton(The Royal Free Hospital), Y. Kondoh(Tosei General Hospital), V. Smith(Ghent University Hospital), John T. Huggins(Medical University of South Carolina), G. Riemekasten(Charité - Universitätsmedizin Berlin), Bruno Crestani(Inserm), M. Alves(Boehringer Ingelheim (Germany)), Alain Lescoat(Inserm), Christian Stock(University of Lübeck), Martina Gahlemann(Boehringer Ingelheim (Switzerland)), M.P. Patel(NewYork–Presbyterian Hospital)
Cited by 0
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
|Annals of the Rheumatic Diseases|2003|769
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
|The Lancet Respiratory Medicine|2020|558
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503